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A Review of Dabigatran, an Oral Anticoagulant 
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Abstract 
Senous c1~:ca 1 compicat1e>ns as30Crated with venous thromootx: 
emlx>llSm (VTE) necess tate prophylaxis 1n patient grouµ; who are at 
hrgh nsk of VTE speed ca Uy rhose recovenng from orthopedic surgery 
w11h atrial f1bnlla11on, w th rnechancal heart valves, at 1rx:reased risk 
for stroke, or recovenng post·MI Currently, prophylaxis with wartann, 
enoxapann. or londaparinux has been the standard of 1heraJJ1, txlt 
these therapies each have their l1m1ta11ons 
Dabgatran etexdate IS an orally available pro-drug of dabgatran, 
a com~111rve, revera1ble. direct 1m1b.torol lhromb1n (Factor llai The 
agent 18 convened by os1emses, and, thus, not associated with the 
comphcat1e>ne ol tlvl CYP enzyme system. Dablgatran follows a linear 
dose -reSJX>llS9 curve a1mpldy1ng dosing com~red to other agents. In the 
BISl RO II study a dose as low u 50 mg dabgatran was fourd to be 
non- n'gnor IO the cUrl9nt standard ol theral'f ol 40 mg enoxa~nn, ard 
BISTRO I ard I~ RE·NOVATE. and RE·l Y all fourd dabgatran was bet-
ter or eq1J1Valenl to V<ilr1ann !IY.lra17f for {X)St -h1pard knee rep/acelll:!n:s. 
Datxgauan could be esp9C1ally benehcial •n patients who have 
a con:ra1ndcabon to wartann. need long-term amicoagulawn ano 
requ re less pauen1 montonng W~h FDA approval ard release of this 
drug tJJne provdil salery and e• acy data to sohd .. -'y dabiga.."'B.n's 
?ace Ill therapy along cumint arJ1-coagula1ion guide fines 
Background 
Anocoagutants have commonly been used for the treatment of venous 
thromboemlX>bsm (VTE) and SllOM! preventJOn. VTE is a llfe-lllrearening 
comphcaoon consisting or either e deep vein thrombosis (DVT) or pul-
monary emboltSm (PE) lmmoblhty of post-surgical orthopedic paoonts, 
commonly h1pand knee replecem9nts, puts these patients at notable 
nsk for teial VTEs. Other spac1f1c pa tient groups et nsk for thrombotic 
events include tnose with etnal hbrlllat1on (a-f1b) or mechanical valVe re-
placements. Patients at nsk for slioke, as well as at nsk post-myocardial 
infarction paoents, also benefit from anticoagulation therapy. Due to 
senous cltnical comphcauons associated with thrombotic events, such as 
stroke, death. loss of hmb, blocked blood vessels or difficulty breathing 
a prophylaxis regimen IS vital fo1 piuents following surgery or those with 
increased nsk for an event 1 3 
Pos1-surgery IOw molecular we9ht heparin (LMWH). such as enox-
apann (lovenox®) and factor Xa mh1bilors Ilka fondapannux (Anxrra® • 
are typically used for prevent10n o' thrombobC events The American 
Ches1 Physicians Evdence·Based Clinical Practx:e Gutdelmes recom-
mend prophylaxis sran ether before or as soon as possible after surgery 
and con[!nue uni the patient IS fuly ambulatory. However ttus regillle'l 
is otren d mcu t because 11 requ res en 1n,ection, and tnere is a jX)SSib cy 
or poor paoont aonerance Haper induced thrombocytopenia HT atso 
presents as a nsl< for pall9nts on LMWH therapy An oral agent w lhout 
tne risk of HIT would be preferred The current oral standard of therapy 
is warfann, a v1tam1n K aniagonist that is commonly used for a-fib 
paoonts as well as any patM!nts 1nd1Cated for long-term anbeoagulaoon. 
Factor Vila 
! ~--tllli• I Factor Xa I 
( Dabgatran ) 
! 
--tllli~ Thrombn (Ila) Prothrombin (II) '----.l xJ 
Figure 1: Target of dabtgatran on clomng cascaoe 
Wany ssues make !he clinical use of warfaM dlf!i:u r. including high 
paoont vanablhty many food and drug 1nterac10ns nvolvmg the CYP450 
enzyme system and diets varying m levets of vrramin K This therapy 
requires substantial monuonng ot PT /INR levels ID ensure panents fall 
w1th1n a narrow therapeutic range ThlS therapy can be dlfftcult, leadtng 
to a high proportion of patients outside or therr therapeur.:: range at any 
given ame With low PT/INR, pat19nts are et nsk for VTE , and with high 
levels. patients are at risk for stroke or hemonhage. Due to the difficulty 
of treatment, warfann-1nduced necrosis, contramd1cat1ons to wartann 
and those who have trouble understanding changes in dosages, wartarin 
1s not a good therapy option for all candidates 16 
Drug informallon 
Dablgatran etex1late 1s an ora lly available pro-::lrug of dabigatran, a 
oompenove reversible, direct tnhtbltor of thronbln (Factor Ila) (Figure 
1 The drug has last onset, peaking two hours after admrmstralion and 
a half-life of 12-17 hours Oablgatran IS conve'ted by esrerases and nor 
by ltle CYP enzyme system, and 80 percent is excreted by the :OOreys 
unchanged Other available agents 1n the d re-:t thrnmtxn 111h b!torclass 
llV:lude b!valiruclin, lepirud1n and argaoooon, which are a •nJ!Ctable.' 
Phannacoklnellcs/Phannacodynamlcs 
Crea an "9 clearance (CrCI) has shown to alfe:t the ctearaoce of dal>-
tgatran but may not be cllnically sigmlicant. SlllCe plasma concentraoollS 
in renally impaired pat10nts are S11T11lar with le"91s m heaJihy panents 
Pa1.1a11ts w1U1 l:I CrCI ul la:;s !11<111 30 rnl/111111 waie not 1r.;luded 111 llle 
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studies, so safety has not ooen confirmed in this patient population. In 
three studies , men and women were shown to have different plasma 
concentrations of dab1ga1ran, with women having slightly higher concen-
trations. This could potentially be explained by increased overall body 
fat distribution, decreased muscle mass and smaller volume of d1stnbu-
tion.8 10 Reduced renal clearance could affect bleeding nsk in high doses 
of uabigalran shown by BISTRO I, wllict1 rou11u110 1napr lJleedi11g unlll 
reaching 300 mg of dabigatran twee daily. 11 Therefore, higher doses of 
dabigatran should oo avoided or monitored closely in patients with renal 
impairmenL 
In a small study, patients with moderate hepatic impairment exhibited 
similar plasma concentrations of dabigatran when compared to healthy 
males. 10 The study found slightly less activation of the pro-drug, but the 
study was not large enough to make a conclusion of clinical significance. 
Absorption of dabigatran reqwres an acidic environment and could be af-
fected by venation m gastnc pH. The dosage form of dabigatran etexilate 
studied is formulated with tartaric acid to standardize the microenv1ron-
ment which hefµ; increase dissolLtion and absorption. 11 B1oavailab1l1ty ts 
lowered to some extent by co-administration of proton pump 1nh1bltors. A 
PK study m the elderty (n=35) found use of pantoprazole with dabigatran 
to decrease dab1gatran absorpt1or by 20-25 percent8 The authors claim 
there 1s no chmcal s1gmfK:ance, but 1t has not yet ooen proven rn a larger 
study. Bioavallabihty has ooen studied in both fasting and fatty meals but 
has not ooen shown to oo affected by either. 
Efficacy 
All of the studies assigned VTE rates as primary or secondary out-
comes. BISTRO I and RE-NOVATE evaluated efficacy of dabigatran m 
total hip replacement patients, and BISTRO II expanded upon BISTRO 
I by including total knee replacements. RE-LY evaluated dabigatran 
in patients with a-fib.4 The rrials ccncluded dabigatran is either oocter 
or equivalent to warfarin therapy for these conditions. Lower rates of 
DVT were found with higher doses of dabigatran. The BISTRO II study 
concluded the lowest rate of VTE was found with 225 mg twice a day." 
In the same study, a dOse as low as 50 mg dabigatran was found to oo 
non-infenor to the current standard of therapy of 40 mg enoxaparin. 
In the RE-LY study, which studied dab1gatran in a-fib patients, 110 mg 
of dabigatran was shown to oo non-inferior to warfarin, while 150 mg 
actually performed better than warfarin. Warfarin had fewer incidences 
of myocardial rnfarctJon compared to dab1gatran, but the 150 mg dab-
igatran dose prevented more strokes. RE-NOVATE found no absolute 
difference or rates between the two groups of dabigatran and enox-
aparin with ma pr VTE or thrombosis-related death. 15 RE-MOBILIZE. 
which evaluated dabigatran in knee arthroplasty surgery patients, found 
enoxapann to tJe more efficacious than dabigatran, concluding dabiga-
tran had a higher risk of VTE and I/TE-related mortality. 10 The authors 
suggested thlS result was because of the more intense, prolonged 
dosing of enoxaparin and the different European procedure that was 
used during trial. The other studies outweigh the negative results of 
RE-MOBILIZE and the indifferent results of RE-NOVA TE by involving 
more Chan 20,000 pallents compared to 1,896 and 3,493 patients m the 
other cnals, respectJVely. More rnals should oo done on a larger scale co 
solidity or disregard the two former srudles' evidence. 
Several of the studies allowed the use ot aspirin (doses <160 mg), 
COX-2 mh1b1tors and compression stockings during the tnals without 
wnside1ing Ule erreclS on U1e results. Duriny a review, Eriksson ad-
dressed the aspirin issue stating no platelet aggregation was seen when 
admm1Stenng dab1gatran along with aspmn. Preliminary data shows 
potenaal increased bleeding when aspmn 1s used with higher doses of 
dab1gatran.15 
Although dab1gatran studies have several valid pomts, flaws m tnal 
design oocome the limiting factors to validity of findmgs. BISTRO II and 
RE-NOVATE l1av(:l i11au(:l4ual(:l or lack or µroper venog1aphies, a11cl wlt1 
studies had high dropout rates. These same two studies also failed to 
take into account the use of aspirin, COX-2 inhibitors or compression 
stockings. Lack of blinding and misuse of power also limit vanous trials. 
Many articles do not show calculations for power or use the statistic 
properly. 14,15 
Safety 
Dablgatran has t:Jeen found to be safe according BISTRO I, BISTRO 
II and the RE-LY studies. All three studies found dabigarran follows a 
hnear dose-response curve, making dosing easier than other agents. 
In BISTRO I and BISTRO II, there were no mapror clinically significant 
ma pr bleeding issues for 150 or 300 mg doses.11 RE-LY found similar 
results, although further data showed, at 150 mg, there were comparable 
bleeds to warfann. It may be of clinical benefit to dose panents at 110 
mg for fewer ma pr bleeds and hosp1tal1zat1ons.4 RE-NOVATE confirmed 
safety by finding no substantial differences for mapr bleedmg events be-
tween dabigatran doses 220 mg or 150 mg compared to enoxaparin 40 
mg (p=0.44 for 220 mg and p=0.6 for 150 mgi 15 However, results from 
PETRO. a study comparing dabigatran to wararin with and without as-
pirin in patients with atrial fibrillation, suggest dabigatran may be unsafe 
with aspirin at high doses. A 300 mg dose along with aspirin was found 
to cause ma pr hemorrhage and was discontinued.17 Significant differ-
ences ootween the dab1gatran groups and enoxaparin were found when 
comparing bleeding event frequencies. In the RE-COVER trial. which 
evaluated dab1gatran versus warfarin in patients with acute venous 
thromboemobohsm, 9 percent of patients taking dabigatran discontinued 
use due ro adverse drug effects, compared with 6.8 percent of patients 
taking warfann. This difference was nor explained by the authOrs. 13 
The overall result was more total bleeds In the warfann group. The tnal 
found dyspepsia as the most common adverse effect of dablgatran. One 
potenllal safety issue is the long haft-life making revers1b11fty difficult 111 
a hemorrhage situation, especially smce there 1s no anttclote. A study 
by Stang1er deemed a drug interaction with atorvastatJn was cllmcally 
1ns1gnificant ma study, with its concentrations being mcreased by 18 
percent, and caused an 18 percent decrease in dabigatran concentration 
when taken concomitan tly.9 Finally, patients on verapamil, amiodarone 
orquinidine have P-glycoprotein interactions, causing a significant rise in 
dabigatran serum concentrations. Concluding information regarding the 
safety of dabigatran is difficult to assess with direct comparison to other 
agents, as tnals have been designed following various standardized 
guidelines. Further trials with more patients and a comparison to current 
U.S. guidelines would help in making a strong argument for Food and 
Drug Administration (FDA) approval. 
Where Is it useful? 
Due to its oral availability and low nu moor of known 1nteract10ns, dab1ga-
tran could oo used clinically for post-orthopedic surgery in both hip and 
knee patients and in a-fib patients. Although not currently rnsearched, 
lung-101111 anticoagulalio11 witll uabiyanan rnay be useful 111 heart valve 
replacement patients. Dabigatran could oo especially ooneficiaJ 1n pa-
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tients who have a contraindication to warfarin and are in need of long-term 
ant1COagulat10n. This med1canon may replace warfann in patients receiv-
ing it as prophylaxis after a VTE. Dab1gatran offers an orally available 
patient option with the JX)ss1b11ity cf lower patient stroke and hemorrhage 
risk, while requiring less patient monitoring. 
Wafann therapy leaves patients at a heightened risk for intracranial 
tnm1urrl1ages, which uwulvl:l l.JuU1 ller11orrl1ayl!,; sliuke C111u suWucal or 
subarachnotd hemorrhages. Although intracranial hemorrhages only occur 
in Q.3 percent of patients on warfann, they account for 90 percent of the 
death and disabilities associated with hemorrhages. 19 In the RE·L Y trial, 
dabigatran was shown to have a similar bleeding risk; however, signifi. 
cantly less intracranial bleeds occurred in both dabigatran groups (0.23 
percent in the 110 mg group and 0.3 percent in the 150 mg group) than 
the warfarm group (0. 7 4 percent). 4 A review of the RE-LY trial stated that 
for every 357 patients treated with 150 mg of dab1gatran rather than war-
farin, one hemorrhagic stroke will be prevented.20 Patients who commonly 
fall may not be good candidates for warfarin due to the risk of 1ntracramal 
hemorrhage. Dabigatran could find a pivotal place in therapy by balancing 
the risk of an 1ntracranial hemorrhage with the prevention of a VTE while 
still allowing the patient to be on an oral medication. 
Whtie dabigatran may be useful 1n specific patients, widespread use 
wi ll not occur untJI more evidence supports it as a warfann replacement 
The cost of the brand-name dab1gatran will likely hinder its prescnb1ng 
until further studies have shown a cos t-benefit over traditional warfann 
and enoxaparin treatment regimens. While the potential cost to U.S. 
patients is not yet known, in !retard, a month supply of 5 mg warfarin 
is approximately $3.55 compared to a month supply of dabigatran at 
$239.55. Dabigatran has a JX)tential cost advantage in that there is little 
to no monitoring required, and the novel agent could reduce the cost of 
treating complications of warfarin misuse. Hindrances to use of dabigatran 
include JX)tential interaction with drugs such as PPls and difficulty dosing 
in renally 1mpa1red patients. Dabigatran is advantageous in hepattcally 
impaired patients due to its activation by esterases and 80 percent renal 
excretion. Oabigacran does not have interactions with vitamin K·coma1nrng 
foods, other medicabOns metabolized by cytochrome P450s or frequent 
PT/INR monuonng.2' 
Based on current evidence, clincally dabigatran has a great potentral 
for therapy for both post-hospitalization and prevenaon of clotting in 
certain JX)ptJlabOns. With FDA approval and release of this drug, time 
wi ll provide safety and efficacy data to solidify the place of dabigatran in 
therapy along current anticoagulation guide Imes. 
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